Early thrombolysis for the treatment of acute myocardial infarction: a systematic review and economic evaluation.
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
The efficacy and safety of fibrinolytic agents have not dramatically changed since alteplase (Activase), a derivative of tissue plasminogen activator (t-PA), was introduced nearly 2 decades ago. However, newer agents have a longer half-life, making them easier to deliver. Fibrinolytic therapy is underused in many patients, especially in those traditionally thought to be at high risk for complications.
Explore the source record for details and available documents.
In this article Nick Castle explains that, with significant improvements being made to the emergency management of cardiac patients, emergency nurses should challenge and develop their clinical practice to ensure patients receive prompt and evidence based treatment.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
BACKGROUND: Inflammation plays a crucial role in atherosclerotic processes and in acute coronary syndromes (ACS). Strong evidence of this is the elevation of C-reactive protein (CRP) serum levels during an ACS and its short- and long-term prognostic potency. The present study aimed to assess the relation between CRP serum levels and the elevation of cardiac markers in patients with ST elevation acute myocardial infarction (STEMI) as well as the effect of intravenous thrombolysis on a time series of CRP values. METHODS: Thirty-six patients with STEMI were enrolled in the study. Twenty-eight of them received intravenous thrombolysis successfully and 8 did not receive thrombolysis. We measured serum concentrations of CRP, troponin I, creatine kinase, creatine kinase isoenzyme and lactate dehydrogenase in all patients on admission, 24 and 48 hours later. CRP serum values were obtained using the turbidimetric method. Coronary angiography was performed in all patients to estimate disease severity and culprit vessel flow after treatment. RESULTS: Patients who were thrombolysed had lower CRP values on admission (p < 0.05), at 24 hours (p < 0.001) and 48 hours later (p < 0.05), compared to those without thrombolysis. CRP values on admission had a positive correlation with markers of cardiac myocyte necrosis and a negative correlation with TIMI flow. CONCLUSION: Thrombolytic therapy in patients with STEMI is associated with a less pronounced response of CRP during the first 48 hours. The close relation of CRP with cardiac enzymes and troponin I on admission adds to the proven value of this inflammatory marker and suggests directions for further research.